Calcium phosphate nanoparticles for transcutaneous vaccine delivery

Journal of Biomedical Nanotechnology

Volumn 9, Issue 1, 2013, Pages 132-141

  Sahdev, Preety ^a   Podaralla, Satheesh ^a,b   Kaushik, Radhey S ^a   Perumal, Omathanu ^a  

^a SOUTH DAKOTA STATE UNIVERSITY   (United States)

^b SRI INTERNATIONAL   (United States)

Author keywords

Adjuvant; CAP Nanoparticles; Tape Stripping; Transcutaneous Vaccination

Indexed keywords

ADJUVANT; CALCIUM PHOSPHATE NANOPARTICLES; NANOPRECIPITATION METHOD; POSITIVE CONTROL GROUP; SEQUENTIAL ADSORPTION; SPLENOCYTE PROLIFERATION; TAPE STRIPPING; TRANSCUTANEOUS VACCINATIONS;

ANTIBODIES; CALCIUM PHOSPHATE; MAMMALS; VACCINES; ZETA POTENTIAL;

NANOPARTICLES;

CALCIUM PHOSPHATE; CALCIUM PHOSPHATE NANOPARTICLE; CARBOHYDRATE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; NANOPARTICLE; OVALBUMIN; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG; VACCINE;

ADSORPTION KINETICS; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; ATENUATED TOTAL REFLECTANCE; ATOMIC FORCE MICROSCOPY; CELL PROLIFERATION; CONTROLLED STUDY; DYNAMIC LIGHT SCATTERING; FEASIBILITY STUDY; FEMALE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; LIGHT SCATTERING; MOUSE; NONHUMAN; PARTICLE SIZE; PH; SPLEEN CELL; STRATUM CORNEUM; ZETA POTENTIAL;

ADMINISTRATION, CUTANEOUS; ADSORPTION; ANIMALS; CALCIUM PHOSPHATES; CARBOHYDRATES; DRUG DELIVERY SYSTEMS; FEMALE; IMMUNITY; IMMUNOGLOBULIN G; LIGHT; MICE; MICE, INBRED BALB C; MICROSCOPY, ATOMIC FORCE; NANOPARTICLES; OVALBUMIN; SCATTERING, RADIATION; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SPLEEN; VACCINES; WATER LOSS, INSENSIBLE; X-RAY DIFFRACTION;

EID: 84876559828     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2013.1545     Document Type: Article

References (51)

1. P. H. Lambert and P. E. Laurent, Intradermal vaccine delivery: Will new delivery systems transform vaccine administration. Vaccine 26, 3197 (2008).
2. J. D. Bos and M. M. Meinardi, The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp. Dermatol. 9, 165 (2000).
3. G. M. Glenn, D. N. Taylor, X. Li, S. Frankel, A. Montemarano, and C. R. Alving, Transcutaneous immunization: A human vaccine delivery strategy using a patch. Nat. Med. 6, 1403 (2000).
4. G. M. Glenn, R. T. Kenney, L. R. Ellingsworth, S. A. Frech, S. A. Hammond, and J. P. Zoeteweij, Transcutaneous immunization and immunostimulant strategies: Capitalizing on the immunocompetence of the skin. Expert. Rev. Vaccines 2, 253 (2003).
5. P. G. Van Der Valk and H. I. Maibach, A functional study of the skin barrier to evaporative water loss by means of repeated cellophanetape stripping. Clin. Exp. Dermatol. 15, 180 (1990).
6. R. Kahlon, Y. Hu, C. H. Orteu, A. Kifayet, J. D. Trudeau, R. Tan, and J. P. Dutz, Optimization of epicutaneous immunization for the induction of CTL. Vaccine 21, 2890 (2003).
7. D. M. Frerichs, L. R. Ellingsworth, S. A. Frech, D. C. Flyer, C. P. Villar, J. Yu, and G. M. Glenn, Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch. Vaccine 26, 2782 (2008).
8. S. Mitragotri, Immunization without needles. Nat. Rev. Immunol. 5, 905 (2005).
9. G. M. Glenn and R. T. Kenney, Mass vaccination: Solutions in the skin. Curr. Top Microbiol. Immunol. 304, 247 (2006).
10. G. M. Glenn, T. Scharton-Kersten, and C. R. Alving. Advances in vaccine delivery: Transcutaneous immunization. Expert Opin. Investig Drugs 8, 797 (1999).
11. R. Tierney, A. S. Beignon, R. Rappuoli, S. Muller, D. Sesardic, and C. D. Partidos, Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses. J. Infect. Dis. 188, 753 (2003).
12. K. Fujihashi, T. Koga, F. W. Van Ginkel, Y. Hagiwara, and J. R. McGhee, A dilemma for mucosal vaccination: Efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 20, 2431 (2002).
13. M. A. Aprile and A. C. Wardlaw, Aluminum compounds as adjuvants for vaccine and toxoids in man: A review. Can. J. Pub. Health. 57, 343 (1996).
14. M. Erodohazi and R. L. Newman, Aluminum hydroxide granuloma. Br. Med. J. 3, 621 (1971).
15. C. Durand, A. Pineau, B. Burcau, and J. F. Stalder, Complications cutanees des vaccinations diptheric, tetanus, coqucluche, poliomyelite (tetracoq) role de l' hydroxide d' alumine. Nouv. Dermatol. 11, 523 (1992).
16. R. K. Gupta, Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv Rev. 32, 155 (1998).
17. E. H. Relyveld, Preparation and use of calcium phosphate adsorbed vaccines. Dev. Boil. Stand. 65, 131 (1986).
18. Y. Wu, W. Jiang, X. Wen, B. He, X. Zeng, G. Wang, and Z. Gu, A novel calcium phosphate ceramic-magnetic nanoparticle composite as a potential bone substitute. Biomed. Mater. 5, 15001 (2010).
19. M. Singh, J. R. Carlson, M. Briones, M. Ugozzoli, J. Kazzaz, J. Barackman, G. Ott, and D. O'Hagan, A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. Vaccine 16, 1822 (1998).
20. R. K. Gupta, B. E. Rost, E. Relyveld, and G. R. Siber, Adjuvant properties of aluminum and calcium compounds. Pharm Biotechnol. 6, 229 (1995).
21. Q. He, A. R. Mitchell, S. L. Johnson, C. Wagner-Bartak, T. Morcol, and S. J. Bell, Calcium phosphate nanoparticle adjuvant. Clin Diagn Lab Immunol. 7, 899 (2000).
22. A. K. Goyal, A. Rawat, S. Mahor, P. N. Gupta, K. Khatri, and S. P. Vyas, Nanodecoy system: A novel approach to design hepatitis B vaccine for immunopotentiation. Int. J. Pharm. 309, 227 (2006).
23. Q. He, A. Mitchell, T. Morcol, and J. D. Bell Steve, Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2. Clin Diagn Lab Immunol. 9, 1021 (2002).
24. N. Kossovsky, A. G. Rajguru, R. Nguyen, E. Sponsler, H. J. Hnatyszyn, K. Chow, A. Chung, M. Torres, J. Zemanovich, J. Crowder, P. Barnajian, K. Ly. Philipose, D. Ammons, S. Abderson, C. Goodwin, P. Soliemanzadeh, G. Yao, and K. Wei, Control of molecular polymorphisms by a structured carbohydrate/ceramic delivery vehicle-aquasomes. J. Control Release 39, 383 (1996).
25. A. K. Goyal, K. Khatri, N. Mishra, A. Mehta, B. Vaidya, S. Tiwari, and S. P. Vyas, Aquasomes - A nanoparticulate approach for the delivery of antigen. Drug Dev. Ind. Pharm. 34, 1297 (2008).
26. R. Oviedo, R A. Salazar-Lopez, J. R. Gasga, and C. T. Quirino- Barreda, Elaboration and structural analysis of aquasomes loaded with Indomethacin. Int. J. Pharm. 32, 223 (2007).
27. A. K. Cherian, A. C. Rana, and S. K. Jain, Self assembled carbohydrate stabilized ceramic nanoparticles for the parenteral delivery of insulin. Drug Dev. Ind. Pharm. 26, 459 (2000).
28. A. Laurentin and C. A. Edwards, A microtiter modification of the anthrone-sulfuric acid colorimetric assay for glucose-based carbohydrates. Anal. Biochem. 315, 143 (2003).
29. L. Yuan, L. Wu, J. Chen, Q. Wu, and S. Hu, Paclitaxel acts as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice. Vaccine 28, 4402 (2010).
30. J. M. Dwyer and C. Johnson, The use of concanavalin A to study the immunoregulation of human T cells. Clin Exp. Immunol. 46, 237 (1981).
31. R. Palacios, Concanavalin A triggers T lymphocytes by directly interacting with their receptors for activation. J. Immunol. 128, 337 (1982).
32. S. Bisht, G. Bhakta, S. Mitra, and A. Maitra, pDNA loaded calcium phosphate nanoparticles: Highly efficient non-viral vector for gene delivery. Int. J. Pharm. 288, 157 (2005).
33. T. Akagi, M. Baba, and M. Akashi, Biodegradable nanoparticles as vaccine adjuvants and delivery systems: Regulation of immune responses by nanoparticle-based vaccine. Adv. Polym. Sci. 247, 31 (2012).
34. A. J. Khopde, S. Khopde, and N. K. Jain, Development of hemoglobin aquasomes from spherical hydroxyapatite cores precipitated in the presence of half generation poly-amidoamine) dendrimer. Int. J. Pharm. 241, 145 (2002).
35. S. Schweizer and A. Taubert, Polymer controlled, bio inspired calcium phosphate mineralization from aqueous solution. Macromol. Biosci. 7, 1085 (2007).
36. M. Epplea and A. Kovtunb, Functionalized calcium phosphate nanoparticles for biomedical application. Key Eng. Mat. 441, 299 (2010).
37. S. Nayar, M. K. Sinha, D. Basu, and A. Sinha, Synthesis and sintering of biomimetic hydroxyapatite nanoparticles for biomedical applications. J. Mater. Sci. 17, 1063 (2006).
38. N. Kossovsky, A, Gelman, E. E. Sponsler, H. J. Hnatyszyn, S. Rajguru, M. Torres, M, Pham, J. Crowder, J. Zemanovich, A. Chung et al., Surface modified nanocrystalline ceramics for drug delivery applications. Biomaterials 15, 1201 (1994).
39. S. Patil, S. S. Pancholi, S. Agrawal, and G. P. Agrawal, Surface modified mesoporous ceramics as delivery vehicle for haemoglobin. Drug Delivery 11, 193 (2004).
40. E. J. Cohn and J. T. Edsall, Proteins, Amino Acids, and Peptides, edited by, Reinhold Publishing Corp, New York (1943).
41. M. E. Goldberg and A. F. Chaffotte, Undistorted structural analysis of soluble proteins by attenuated total reflectance infrared spectroscopy. Protein Sci. 14, 2781 (2005).
42. B. G. Zanetti-Ramos, M. B, Fritzen-Garcia, C. S. De Oliveira, A. A. Pasa, V. Soldi, R. Borsali, and T. B. Creczynski-Pasa, Dynamic light scattering and atomic force microscopy techniques for size determination of polyurethane nanoparticles. Materials Science and Engineering, C 29, 638 (2009).
43. C. M. Hoo, N. Starostin, P. West, and M. L. Mecartney, A comparison of atomic force microscopy and dynamic light scattering (DLS) methods to characterize nanoparticle size distributions. J. Nanopart Res. 10, 89 (2000).
44. V. Kanchan, Y. K. Katare, and A. K. Panda, Memory antibody response from antigen loaded polymer particles and the effect of antigen release kinetics. Biomaterials 30, 4763 (2009).
45. J. W. Streilein, L. W. Lonsberry, and P. R. Bergstresser, Depletion of epidermal langerhans cells and Ia immunogenicity from tapestripped mouse skin. J. Exp. Med. 155, 863 (1982).
46. N. Seo, Y. Tokura, T. Nishijima, H. Hashizume, F. Furukawa, and M. Takigawa, Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Proc. Natl. Acad. Sci. USA 97, 371 (2000).
47. T. Nishijima, Y. Tokura, G. Imokawa, N. Seo, F. Furukawa, and M. J. Takigawa, Altered permeability and disordered cutaneous immunoregulatory function in mice with acute barrier disruption. Invest Dermatol. 109, 175 (1997).
48. L. C. Wood, K. R. Feingold, S. M. Sequeira-Martin, P. M. Elias, and C. Grunfeld, Barrier function coordinately regulates epidermal IL-1 and IL-1 receptor antagonist mRNA levels. Exp. Dermatol. 3, 56 (1994).
49. B. J. Nickoloff and Y. Naidu, Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J. Am. Acad. Dermatol. 30, 535 (1994).
50. N. A. Hosken, K. Shibuya, A. W. Heath, K. M. Murphy, and A. J. O'Garra, The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. Exp. Med. 182, 1579 (1995).
51. F. Castellino, G. Galli, G. Del Giudice, and R. Rappuoli, Generating memory with vaccination. Eur. J. Immunol. 39, 2100 (2009).